(Q36492310)

14 August 2017

1 reference

title

Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

2

Thomas Foltynie

1 reference

14 August 2017

4

Roger A Barker

1 reference

14 August 2017

3

Simon J G Lewis

1 reference

14 August 2017

author name string

Caroline H Williams-Gray

series ordinal

1

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

477-505

1 reference

Risk factors for nursing home placement in advanced Parkinson's disease.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Cognitive status correlates with neuropathologic stage in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Cognitive change following MPTP exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620060-00004

Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

21 January 2018

1 reference

12 December 2020

Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease

1 reference

12 December 2020

The impact of deep brain stimulation on executive function in Parkinson's disease.

1 reference

12 December 2020

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

1 reference

12 December 2020

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

1 reference

12 December 2020

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

Fronto-striatal cognitive deficits at different stages of Parkinson's disease

1 reference

12 December 2020

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

12 December 2020

A subcortico-cortical cholinergic system is affected in Parkinson's disease.

1 reference

12 December 2020

What's atypical about atypical antipsychotic drugs?

1 reference

12 December 2020

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

1 reference

12 December 2020

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

1 reference

12 December 2020

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

1 reference

12 December 2020

Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease.

1 reference

12 December 2020

Visuospatial impairment in Parkinson's disease

1 reference

12 December 2020

Cholinergic-dependent cognitive deficits in Parkinson's disease.

1 reference

12 December 2020

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

1 reference

12 December 2020

The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study

1 reference

12 December 2020

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

12 December 2020

What contributes to quality of life in patients with Parkinson's disease?

1 reference

12 December 2020

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

1 reference

12 December 2020

Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.

1 reference

12 December 2020

Risperidone treatment of drug-related psychosis in patients with parkinsonism

1 reference

12 December 2020

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

12 December 2020

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

Dementia associated with Parkinson's disease

1 reference

12 December 2020

Basal forebrain neurons in the dementia of Parkinson disease

1 reference

12 December 2020

Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease.

1 reference

12 December 2020

Intellectual changes in patients with MPTP-induced parkinsonism

1 reference

12 December 2020

Clozapine. A novel antipsychotic agent

1 reference

12 December 2020

Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement

1 reference

12 December 2020

Intrinsic and extrinsic psychosis in Parkinson's disease

1 reference

12 December 2020

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study

1 reference

12 December 2020

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

1 reference

12 December 2020

Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease

1 reference

12 December 2020

Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction

1 reference

12 December 2020

Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.

1 reference

12 December 2020

Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.

1 reference

12 December 2020

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

1 reference

12 December 2020

Range of neuropsychiatric disturbances in patients with Parkinson's disease

1 reference

12 December 2020

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

1 reference

12 December 2020

Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action

1 reference

12 December 2020

Neuropathology of dementia in Parkinson's disease: A prospective, community-based study

1 reference

12 December 2020

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

1 reference

12 December 2020

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

1 reference

12 December 2020

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.

1 reference

12 December 2020

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

12 December 2020

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia

1 reference

12 December 2020

Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness

1 reference

12 December 2020

Auditory hallucinations in Parkinson's disease

1 reference

12 December 2020

Hallucinations in Parkinson's disease: the clinical syndrome.

1 reference

12 December 2020

alpha-Synuclein locus triplication causes Parkinson's disease

1 reference

12 December 2020

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

1 reference

12 December 2020

Cognitive enhancing effects of modafinil in healthy volunteers

1 reference

12 December 2020

Psychosis in Parkinson's disease

1 reference

12 December 2020

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

1 reference

12 December 2020

Lewy body cortical involvement may not always predict dementia in Parkinson's disease

1 reference

12 December 2020

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

1 reference

12 December 2020

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

1 reference

12 December 2020

Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus

1 reference

12 December 2020

Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia

1 reference

12 December 2020

Regional cerebral blood flow in Parkinson's disease with and without dementia

1 reference

12 December 2020

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

1 reference

12 December 2020

Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy

1 reference

12 December 2020

Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases.

1 reference

12 December 2020

Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease

1 reference

12 December 2020

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

1 reference

12 December 2020

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

1 reference

12 December 2020

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

1 reference

12 December 2020

Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

1 reference

12 December 2020

Dementia and cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain

1 reference

12 December 2020

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

12 December 2020

Clinico-pathological correlations in Parkinson's disease

1 reference

12 December 2020

Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review

1 reference

12 December 2020

Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease

1 reference

12 December 2020

What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications

1 reference

12 December 2020

An estimate of the incidence of dementia in idiopathic Parkinson's disease

1 reference

12 December 2020

Modafinil improves alertness, vigilance, and executive function during simulated night shifts

1 reference

12 December 2020

Rivastigmine for dementia associated with Parkinson's disease

1 reference

12 December 2020

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

1 reference

12 December 2020

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

1 reference

12 December 2020

Behavioral changes associated with deep brain stimulation surgery for Parkinson's disease.

1 reference

12 December 2020

Mechanisms of cognitive set flexibility in Parkinson's disease.

1 reference

12 December 2020

Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease

1 reference

12 December 2020

The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated

1 reference

12 December 2020

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

1 reference

12 December 2020

Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745

1 reference

12 December 2020

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

1 reference

12 December 2020

Drugs to treat dementia and psychosis: management of Parkinson's disease

1 reference

12 December 2020

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

1 reference

12 December 2020

Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma.

1 reference

12 December 2020

Poor visual discrimination and visual hallucinations in Parkinson's disease

1 reference

12 December 2020

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

1 reference

12 December 2020

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study

1 reference

12 December 2020

Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study

1 reference

12 December 2020

Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients

1 reference

12 December 2020

Prospective study of hallucinations and delusions in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

1 reference

12 December 2020

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications

1 reference

12 December 2020

Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.

1 reference

12 December 2020

The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease

1 reference

12 December 2020

Clozapine in Parkinson's disease psychosis: 5-year follow-up review

1 reference

12 December 2020

Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism

1 reference

12 December 2020

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

1 reference

12 December 2020

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

1 reference

12 December 2020

A Population-Based Investigation of Parkinson's Disease With and Without Dementia

1 reference

12 December 2020

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

12 December 2020

Frequency of dementia in Parkinson disease.

1 reference

12 December 2020

Decreased dopamine in the retinas of patients with Parkinson's disease

1 reference

12 December 2020

Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease

1 reference

12 December 2020

Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model

1 reference

12 December 2020

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

1 reference

12 December 2020

1 reference

12 December 2020

The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test.

1 reference

12 December 2020

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

12 December 2020

The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type

1 reference

12 December 2020

Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex

1 reference

12 December 2020

Delusional misidentification in association with parkinsonism

1 reference

12 December 2020

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction

1 reference

12 December 2020

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands

1 reference

12 December 2020

10.2165/00023210-200620060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1038366968

0 references

Fatcat ID

release_izfhnjeuyfgodjsufuqzszaosq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/izfhnjeuyfgodjsufuqzszaosq

24 November 2022

mapped directly with Wikidata item

1 reference